Expertise in
17
conditions

Dr. Dukagjin M. Blakaj

Radiation Oncology
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 
Accepting New Patients
Expertise in
17
conditions
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 

Overview

Dukagjin Blakaj is a Radiation Oncologist practicing medicine in Columbus, Ohio.

Dr. Blakaj is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Laminectomy, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 9 clinical trials. Dr. Blakaj is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in OH

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Ohio State University Hospital-Pavilion
300 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
A Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

144 Total Publications

Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Journal: JAMA otolaryngology-- head & neck surgery
Published: August 27, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Arnab Chakravarti
Radiation Oncology
Expertise in
8
conditions
Dr. Arnab Chakravarti
Radiation Oncology
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.8 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Arnab Chakravarti is a Radiation Oncologist practicing medicine in Columbus, Ohio. Dr. Chakravarti is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. Dr. Chakravarti is currently accepting new patients.

Expertise in
11
conditions
Dr. Allison M. Quick
Radiation Oncology
Expertise in
11
conditions
Dr. Allison M. Quick
Radiation Oncology
Referral may be required

The Arthur G. James Cancer Hospital And Richard J. Solove Research Institute

460 W 10th Ave, 
Columbus, OH 
 (0.2 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Allison Quick is a Radiation Oncologist practicing medicine in Columbus, Ohio. Dr. Quick is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Vaginal Cancer, Cervical Cancer, Vulvar Cancer, and Endometrial Cancer. Dr. Quick is currently accepting new patients.

Expertise in
22
conditions
Dr. Raju R. Raval
Radiation Oncology
Expertise in
22
conditions
Dr. Raju R. Raval
Radiation Oncology
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.8 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Raju Raval is a Radiation Oncologist practicing medicine in Columbus, Ohio. Dr. Raval is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET). Dr. Raval is currently accepting new patients.

Frequently Asked Questions about Dr. Dukagjin M. Blakaj

How do I make an appointment with Dr. Dukagjin M. Blakaj?

You can book an appointment with Dr. Dukagjin M. Blakaj by calling their office at 614-366-7744. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dukagjin M. Blakaj a top-rated expert for Laryngeal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dukagjin M. Blakaj is classified as an Distinguished expert for Laryngeal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dukagjin M. Blakaj specialize in?

While Dr. Dukagjin M. Blakaj is a Radiation Oncology, they have specific expertise in Laryngeal Cancer, Throat Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Dukagjin M. Blakaj participate in research or clinical trials?

Yes. Dr. Dukagjin M. Blakaj has published 144 articles and abstracts on conditions like Laryngeal Cancer. You can view a list of Dr. Dukagjin M. Blakaj's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dukagjin M. Blakaj accept my insurance?

Dr. Dukagjin M. Blakaj accepts most major insurance plans, including CareSource and Humana. We recommend calling the office directly at 614-366-7744 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blakaj's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile